Vallon's abuse-resistant Adderall fails clinical trial, causing stock to crater

Vallon Pharmaceuticals’ abuse-resistant Adderall has flunked a key test. ADAIR performed no better than the reference formulation of the stimulant dextroamphetamine on a measure of abuse liability, causing the trial to miss its primary endpoint and Vallon’s share price to collapse.